[Novel treatment with oncolytic herpes simplex virus, 'HF10' against breast cancer].
An oncolytic herpes simplex virus type 1 mutant, named HF10, has been isolated and evaluated for anti-tumor efficacy in syngeneic immuno-competent mouse models. We have found that the mutant virus can very effectively treat cancer, and that all of survived mice acquire resistance to rechallenge of the tumor cells. Since a number of studies have shown that HF10 is effective and safe for use in localized or peritoneally disseminated malignant tumors of non-neuronal origin, phase I/II clinical trials using HF10 have been initiated for patients with metastatic breast cancer. Preliminary data from the clinical trials are encouraging.
Kimata
Hideto
H
Department of Surgery II, Graduate School of Medicine, Nagoya University.
Teshigahara
Osamu
O
Nishiyama
Yukihiro
Y
Nakao
Akimasa
A
D000818:Animals; D001943:Breast Neoplasms / Q000276:immunology / Q000628:therapy* / Q000821:virology; D002986:Clinical Trials as Topic; D004195:Disease Models, Animal; D018259:Herpesvirus 1, Human / Q000235:genetics / Q000276:immunology*; D006801:Humans; D007167:Immunotherapy / Q000379:methods*; D051379:Mice; D009154:Mutation; D011233:Precipitin Tests